Clovis Oncology discontinue phase 2 bladder cancer trial

pharmafile | April 15, 2019 | News story | Sales and Marketing Cancer, Clovis Oncology, US, bladder cancer, metastatic bladder cancer 

Colorado-based pharma firm Clovis Oncology has said in a filing to the US Securities and Exchange Commission that it is discontinuing the phase 2 ATLAS trial of Rubraca (rucaparib) monotherapy in recurrent metastatic bladder cancer.

The decision was based on indications from an independent data monitoring committee. The review of preliminary data from 62 patients found the treatment “may not provide a meaningful clinical benefit.” The decision was not based on safety concern, Clovis said.

The firm said it would continue to assess the use of Rubraca in combination with other treatments for use in patients with advanced bladder cancer.

The US drugmaker has also said it will enrol patients with advanced bladder cancer and selected genetic mutations in a pan-tumour trial of Rubraca slated to start in the second half of the year.

Earlier this month, Clovis presented Phase II study results demonstrating that Rubraca led to complete or partial responses in several patients with advanced BRCA- or PALB2-mutated pancreatic cancer.

Louis Goss

Related Content


Innate Pharma announces drug researched with Sanofi receives FDA Fast Track Designation

Innate Pharma has announced that the drug jointly researched between itself and Sanofi has received US …


GRAIL and University of Oxford showcase first prospective study results for multi-cancer early detection test

US-based healthcare company GRAIL and the University of Oxford, UK, have announced encouraging first prospective …

ISA Pharmaceuticals highlights positive clinical data at ASCO

Clinical stage biotechnology company ISA Pharmaceuticals has announced positive phase 1 data at the American …

Latest content